Related Experiment Video
Updated: Jul 23, 2025
Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023
Advances in glioma models using in vivo electroporation to highjack neurodevelopmental processes
Longbo Zhang1, Angelique Bordey2
1Departments of Neurosurgery, Changde hospital, Xiangya School of Medicine, Central South University, 818 Renmin Street, Wuling District, Changde, Hunan 415003, China; Departments of Neurosurgery, and National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, China; Departments of Neurosurgery, and Cellular & Molecular Physiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06520-8082, USA.
Abstract:
Glioma is the most prevalent type of neurological malignancies. Despite decades of efforts in neurosurgery, chemotherapy and radiation therapy, glioma remains one of the most treatment-resistant brain tumors with unfavorable outcomes. Recent progresses in genomic and epigenetic profiling have revealed new concepts of genetic events involved in the etiology of gliomas in humans, meanwhile, revolutionary technologies in gene editing and delivery allows to code these genetic "events" in animals to genetically engineer glioma models. This approach models the initiation and progression of gliomas in a natural microenvironment with an intact immune system and facilitates probing therapeutic strategies. In this review, we focus on recent advances in in vivo electroporation-based glioma modeling and outline the established genetically engineered glioma models (GEGMs).
Insights
This review highlights genetically engineered glioma models (GEGMs) created using advanced gene editing. These models mimic human glioma development in vivo, aiding the study of brain tumors and therapeutic strategies.
Area of Science:
- Neuro-oncology
- Genetics
- Molecular Biology
Background:
- Glioma is a prevalent and treatment-resistant neurological malignancy.
- Traditional therapies show limited success in improving glioma patient outcomes.
- Genomic and epigenetic research has identified key genetic events in glioma etiology.
Purpose of the Study:
- To review recent advances in in vivo electroporation-based glioma modeling.
- To outline established genetically engineered glioma models (GEGMs).
- To discuss the utility of GEGMs for probing therapeutic strategies.
Main Methods:
- Utilizing gene editing and delivery technologies to engineer animal models.
- Employing in vivo electroporation for precise genetic modification.
- Focusing on models that recapitulate glioma initiation and progression.
Main Results:
- GEGMs provide a natural microenvironment with an intact immune system.
- These models facilitate the study of glioma development and response to therapies.
- Advances in electroporation enable sophisticated in vivo glioma modeling.
Conclusions:
- Genetically engineered glioma models represent a significant advancement in brain tumor research.
- GEGMs are crucial for understanding glioma biology and testing novel treatments.
- In vivo electroporation is a key technology for creating these advanced models.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
10:58Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015